Focused Ultrasound-Induced Blood–Brain Barrier Opening to Enhance Temozolomide Delivery for Glioblastoma Treatment: A Preclinical Study
Figure 5
In-vivo TMZ concentration measurement.
(a) Measured TMZ concentrations (in µg/ µL) in cerebrospinal fluid (CSF) and blood plasma in animals treated with TMZ only (TMZ; n = 4) or combined TMZ with FUS-BBB opening (TMZ+FUS; n = 6). (b) Corresponding CSF/Plasma ratios (in %) determined from (a) (p = 0.06).